Curriculum vitae cihan yurdaydin, M. D



Download 101.12 Kb.
Date05.08.2017
Size101.12 Kb.
#26746
CURRICULUM VITAE
CIHAN YURDAYDIN, M.D.


Private: Office:

Eskisehir Yolu, 13.km Ankara University Medical School

Çinar Sitesi, 4. Blok No:30 Section of Gastroenterology

Ümitköy Cebeci Tip Fakültesi Hastanesi

06530 Ankara/Turkey 06100 Ankara/Turkey

Tel: 90-312- 235 7346 Tel: 90-312-595 6110

E-mail: cihan.yurdaydin@medicine.ankara.edu.tr Fax: 90-312-363 62 13
Born January 2, l954, in Montreal, Canada, live in Turkey, Turkish Citizen, married to Hülya Yurdaydin, pharmacist, 2 children.

EDUCATION:

l965-1971 Junior High School

"Istanbul Erkek Lisesi", Istanbul, Turkey

1971-l977 Medical School, University of Ankara, Turkey

MD - Aug. 12, l977

ECFMG - July, l982


POSTGRADUATE TRAINING:

l978-1982 Specialty in Internal Medicine, Department of Internal Medicine, University of Ankara; Specialty Board in Internal Medicine 7/8/82.

1982-1983 Military service, Gümüssuyu Military Hospital, Department of Internal

Medicine


l984-9/86 Obligatory work at VanState Hospital, Department of Internal Medicine,

according to a law for medical doctors in Turkey,

9/86-2/89 Subspecialty Training in Gastroenterology, Department of Gastroenterology, University of Ankara; Specialty Board in Gastroenterology 2/24/89.

1/88-12/88 Visiting Scientist, l. Clinic of Gastroenterology and Hepatology,

University of Vienna, Vienna, Austria (Research in experimental

hepatic encephalopathy)

10/89-9/95 Associate Professor of Medicine at Ankara University Medical School

6/91-6/93 Visiting Associate in the Liver Diseases Section, Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, at the National Institutes of Health, Bethesda, Maryland, USA

9/95 Appointed as Professor of Medicine at Ankara University Medical School
MEMBERSHIPS and ADMINISTRATIVE JOBS:
I am a member of The American Association for the Study of Liver Diseases (AASLD), The European Association for the Study of the Liver (EASL), The Turkish Society for Gastroenterology, The Turkish Association for the Study of the Liver and The Turkish Transplantation Society .

I was a member of the Editorial Board of " Journal of Hepatology " between January 1995 and December 1999.

I am Editor-in Chief of " Turkish Journal of Gastroenterology " since January 1999.

ASNEMGE Executive Member and Head of the Education Committee until 2004

Member of the Scientific Committee of EASL between 2001-2004

Educational Councillor for EASL between 2013-2015

President-elect of the World Gastroenterology Organization since November 2015

AWARDS:


Recipient of the Bayindir Scientific Award: 2012

Recipient of the Science Award of The Scientific and Technological Research Council of Turkey: 2013



CURRENT POSITION:

Professor and Chief of Gastroenterology at the University of Ankara Medical School, Section of Gastroenterology, and Chief of Hepatology Institute of the University of Ankara


Cihan Yurdaydin, M.D.

Professor of Gastroenterology

University of Ankara Medical School

Section of Gastroenterology

Cebeci Tip Fakültesi Hastanesi

Cebeci, 06100 Ankara/Turkey

Fax: 90-312-363 6213

Phone (Office): 90-312-595 6110

Phone (Home): 90-312-235 7346



E-mail: cihan.yurdaydin@medicine.ankara.edu.tr

MANUSCRIPTS PUBLISHED IN INTERNATIONAL
PEER-REWIEWED JOURNALS


  1. Zimmermann C, Ferenci P, Pifl C, Yurdaydın C, Ebner J, Lassmann H, Roth E, Hörtnagl H. Hepatic encephalopathy in thioacetamide induced acute liver failure in rats. Characterization of an improved model and study of aminoacidergic neurotransmission. Hepatology 1989; 9: 594-601.

  2. Yurdaydın C, Hörtnagl H, Steindl P, Zimmermann Ch, Pifl Ch, Singer E, Roth E, Ferenci P: Increased serotoninergic and noradrenergic activity in hepatic encephalopathy in rats with thioacetamide-induced acute liver failure. Hepatology 1990; 12: 695-700.

  3. Yurdaydın C, Gu ZQ, Nowak G, Fromm C, Holt AG, Basile AS. Benzodiazepine receptor ligands are elevated in an animal model of hepatic encephalopathy: relationship between brain concentration and severity of encephalopathy. J Pharmacol Exp Ther 1993; 265: 565-71.

  4. Jones EA, Yurdaydın C, Basile AS. The role of endogenous benzodiazepines in hepatic encephalopathy: animal studies. Alcohol & Alcoholism Suppl, 1993; 2:175-80.

  5. Jones EA, Basile AS, Yurdaydın C, Skoluick P. Do benzodiazepine ligands contribute to hepatic encephalopathy? Adv Exp Med Biol 1993; 341: 57-69.

  6. Örmeci N, Abasıyanık A, Bülbül M, Aka H, Atayurt H, Yurdaydın C, Dökmeci A, Uzunalimoğlu Ö. Endoscopic papillotomy in a child with a biliocutaneous fistula. Endoscopy 1994; 26: 565.

  7. Jones EA, Yurdaydın C, Basile AS. The GABA hypothesis-state of the art. Adv Exp Med Biol 1994; 368:89-101.

  8. Yurdaydın C, Li Y, Rothman R, Jones EA, Basile AS. Brain and plasma levels of opioid peptides are altered in rats with thioacetamide-induced fulminant hepatic failure: implications for the treatment of hepatic encephaloptahy with opiate antagonists. J Pharmacol Exp Ther 1995; 273: 185-92.

  9. Yurdaydın C, Walsh TJ, Engler HD, Ha J-H, Li Y, Jones EA, Basile AS. Gut bacteria provide precursors of benzodiazepine receptor ligands in a rat model of hepatic encephalopathy. Brain Res 1995; 679: 42-8.

  10. Bergasa NV, Alling DW, Talbot TL, Swain MG, Yurdaydın C,Turner ML, Schmitt JM, Walker EC, Jones EA. Effects of naloxone infusions in patients with the pruritis of cholestasis: a double-blind controlled trial. Ann Intern Med 1995; 123: 161-7.

  11. Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydın C, Swain M, Kleiner DE, Mahaney K, Hoofnagle JH. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 897-903.

  12. Yurdaydın C, Herneth AM, Püspök A, Steindl P, Singer EA, Ferenci P. Modulation of hepatic encephalopathy in rats with thioacetamide-induced acute liver failure by serotonin antagonists. Eur J Gastroenterol Hepatol 1996; 8: 667-71.

  13. Beyler AR, Yurdaydın C, Bahar K, Gören A, Soykan I, Uzunalimoğlu Ö. Dilatation therapy of upper esophageal webs in two cases of Plummer-Vinson syndrome: Endoscopy 1996; 28: 266-7.

  14. Jones EA, Yurdaydın C. (Editorial) Is fatigue associated with cholestasis mediated by altered central neurotransmission? Hepatology 1997; 25: 492-4.

  15. Yurdaydın C, Swain MG, Mininberg ED, Vergella J, Kleiner D, Paul SM, Jones EA. Effect of inhibition of ornithine decarboxylase activity in a model of acute hepatocellular necrosis. Eur J Gastroenterol Hepatol 1998; 10: 503-7.

  16. Yurdaydın C, Karavelioğlu D, Onaran O, Çelik T, Yaşa MH, Uzunalimoğlu Ö. Opioid receptor ligands in human hepatic encephalopathy. J Hepatol 1998; 29: 796-801.

  17. Kansu A, Girgin N, Yurdaydın C, Çetinkaya H, Uzunalimoğlu Ö. Hereditary pancreatitis: Report of a family from Turkey. Acta Paeditar Jpn 1998; 40: 612-5.

  18. Çelik T, Uzbay T, Çınar K, Bozkaya H, Uzunalimoğlu Ö, Yurdaydın C. Combination treatment of thioacetamide-induced fulminant hepatic failure in the rat with benzodiazepine and opioid receptor antagonists. J Hepatol 1999; 31: 880-6.

  19. Akbay A, Çınar K, Uzunalimoğlu Ö, Eranıl S, Yurdaydın C, Bozkaya H, Bozdayı AM. Serum cytotoxin and oxidant stress markers in N-acetylcysteine treated thioacetamide hepatotoxicity of rats. Hum Exp Toxicol. 1999; 18: 669-76.

  20. Bozdayı AM, Uzunalimoğlu O, Aslan N, Bozkaya H, Türkyılmaz AR, Kayhan B, Şahin B, Sivri B, Uygun A, Altıok A, Çetinkaya H, Karayalçın S, Yurdaydın C. Influence of viral load and alanine aminotransferase on viral genetic heterogenity in patiens with chronic hepatitis C virus infection. Intervirology 2000; 43: 61-6.

  21. Bozkaya H, Bozdayı AM, Türkyılmaz A, Çetinkaya H, Yurdaydın C, Uzunalimoğlu Ö. TH1/TH2 Cytokines and their relations to HBeAg status and ALT flares in chronic HBV infection. Hepatogastroenterology 2000; 47: 1667-71.

  22. Bozkaya H, Bozdayı AM, Aslan N, Çetinkaya H, Akdoğan M, Şentürk H, Akkız H, Yurdaydın C, Karayalçın S, Uzunalimoğlu Ö. Circulating IL-2 and IL-10 in chronic active hepatitis C with respect to the response to IFN treatment. Infection 2000; 28: 309-13..

  23. Uzunalimoğlu Ö, Yurdaydın C, Çetinkaya H, Bozkaya H, Şahin T, Çolakoğlu S, Tankut E, Sarıoğlu M, Özenirler S, Akkız H, Tözün N. Risk factors for hepatocellular carcinoma in Turkey. Dig Dis Sci 2001 May; 46(5):1022-8.

  24. Yurdaydın C. The central opioid system in liver disease and its complications. Met Brain Dis 2001 Jun; 16 (1-2): 79-83.

  25. Bozkaya H, Bozdayı M , Türkyılmaz R, Sarıoğlu M, Çetinkaya H, Çınar K, Köse K, Yurdaydin C, Uzunalimoğlu O. Circulating IL-2, IL-10 and TNF-alpha in chronic hepatitis B: their relations to HB status and the activity of liver disease. Hepatogastroenterology. 2000 Nov-Dec; 47 (36): 1675-9.

  26. Bozdayı AM, Bozkaya H, Türkyılmaz AR, Saryodlu M, Çetinkaya H, Karayalçın S, Yurdaydin C, Uzunalimoğlu. Nucleotide divergences in the core promoter and precore region of genotype D hepati virus in patients with persistently elevat normal ALT levels. J Clin Virol. 2001 Apr ; 21(1) : 91-101.

  27. Yurdaydin C, Bozkaya H, Gürel S, Tillmann HL, Aslan N, Okcu-Heper A, Erden E, Yalçın K, Iliman N, Uzunalimoglu O, Manns MP, Bozdayı AM. Farmciclovir treatment of chronic delta hepatitis. J Hepatol. 2002 Aug;37(2):266-71.

  28. Bozkaya H, Yurdaydin C, Törüner M, Arat M, Bozdayı AM, Erekul S, Çinar K, Koç H, Uzunalimoğlu O. Remission of severe aplastic anemia asso with hepatitis B virus infection after viral clearance: potential role of lamivudine. Dig Dis Sci. 2002; 47:1782-5.

  29. Bozkaya H, Yurdaydin C, Bozdayı AM, Erkan O, Karayalçın S, Uzunalimoğlu O.. Oral ganciclovir for treatment of lamivudin resistant hepatitis B virus infection: a pilot study. Clin Infect Dis. 2002 ; 35: 960-5.

  30. Erden A, Erden I, Karayalçın S, Yurdayin C. Budd-Chiari syndrome: evaluation with multiphase contrast-enhanced three-dimensional MR angiography. AJR Am J Roentgenol. 2002; 179: 1287-9.

  31. Serinöz E, Varlı M, Erden E, Çinar K, Kansu A, Uzunalimoğlu O, Yurdaydin C, Bozkaya H. Nuclear localization of hepatitis B core ant and its relations to liver injury, hepatocyt proliferation, and viral load. J Clin Gastroenterol 2003; 36:269-72.

  32. Erden A, Erden I, Yagmurlu B, Karayalçın S, Yurdaydin C, Karayalçin K. Portal venous system Evaluation with cont enhanced 3D MR portography. Clin Imaging. 2003; 27:101-5.

  33. Yalçın K, Degertekin H, Yurdaydin C, Bozdayı M, Bozkaya H. The role of HbeAg seroconversion in acute exacerbation of liver disease with termination of hepatitis B and D virus infection in a hepatitis D patient during alpha-interferon therapy. Eur J Gastroenterol Hepatol. 2003; 15: 81.

  34. Bozdayı AM, Uzunalimoğlu O, Türkyılmaz AR, Aslan N, Sezgin O, Şahin T, Bozdayı G, Çinar K, Pai SB, Pai R, Bozkaya H, Karayalçın S, Yurdaydin C, Schinazi RF. YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine. J Viral Hepat. 2003;10:256-265

  35. Yurdaydin C. Blood ammonia determination in cirrhosis: Still confusing after all these years ?. Hepatology 2003; 38:1307-1310

  36. Erden A, Erden I, Yurdaydin C, Karayalcin S. Hepatic outflow obstruction: enhancement patterns of the liver on MR angiography. Eur J Radiol 2003; 48:203-8

  37. Toruner M, Soykan I, Ensari A, Kuzu I, Yurdaydin C, Ozden A. Barrett's esophagus: prevalence and its relationship with dyspeptic symptoms. J Gastroenterol Hepatol. 2004; 19:535-540

  38. Bozkaya H, Bektas M, Metin O, Erkan O, Ibrahimoglu D, Dalva K, Akbiyik F, Gurel S, Bozdayi AM, Akay C, Yurdaydin C, Aslan O, Uzunalimoglu O. Screening for hemochromatosis in Turkey. Dig Dis Sci. 2004; 49:444-449

  39. Akbiyik F, Cinar K, Demirpence E, Ozsullu T, Tunca R, Haziroglu R, Yurdaydin C, Uzunalimoglu O, Bozkaya H. Ligand-induced expression of peroxisome proliferator-activated receptor alpha and activation of fatty acid oxidation enzymes in fatty liver. Eur J Clin Invest. 2004; 34:429-435

  40. Bozdayi AM, Eyigun CP, Turkyilmaz AR, Avci IY, Pahsa A, Yurdaydin C. A novel pattern (sW195a) in surface gene of HBV DNA due to YSDD (L180M plus M204S) mutation selected during lamivudine therapy and successful treatment with adefovir dipivoxil. J Clin Virol 2004; 31:76-77



  1. Karavelioglu D, Koytak ES, Bozkaya H, Uzunalimoglu O, Bozdayi AM, Yurdaydin C. Lichen planus and HCV infection in Turkish patients. Turk J Gastroenterol. 2004; 15:133-136

  2. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM,

Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Button P, Pluck N; Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004; 351:1206-1217

  1. Bozdayi AM, Aslan N, Bozdayi G, Turkyilmaz AR, Sengezer T, Wend U, Erkan O, Aydemir F, Zakirhodjaev S, Orucov S, Bozkaya H, Gerlich W, Karayalcin S, Yurdaydin C, Uzunalimoglu O. Molecular epidemiology of hepatitis B, C and D viruses in Turkish patients. Arch Virol. 2004; 149:2115-2129

  2. Erkan O, Bozdayi AM, Disibeyaz S, Oguz D, Ozcan M, Bahar K, Karayalcin S, Ozden A, Bozkaya H, Yurdaydin C, Uzunalimoglu O. Thrombophilic gene mutations in cirrhotic patients with portal vein thrombosis. Eur J Gastroenterol Hepatol 2005; 17:339-43.

  3. Yurdaydin C, Bozkaya H, et al. Treatment of HBeAg-negative chronic hepatitis B with lamivudine vs. lamivudine + interferon. J Viral Hepat 2005; 12:262-268

  4. Celik T, Goren MZ, Cinar K, Gurdal H, Onder FO, Tan A, Terzioglu B, Bozdayi AM, Bozkaya H, Uzunalimoglu O, Yurdaydin C. Fatigue of cholestasis and the serotoninergic neurotransmitter system in the rat. Hepatology 2005; 41:731-737

  5. Bozkaya H, Yurdaydin C, Idilman R, Tuzun A, Cinar K, Erkan O, Bozdayi AM, Erden E, Uzun Y, Cetinkaya H, Uzunalimoglu O. Lamivudine treatment in HBeAg-negative chronic hepatitis B patients with low level viraemia. Antivir Ther 2005;10:319-25

  6. Bozdayi G, Turkyilmaz AR, Idilman R, Karatayli E, Rota S, Yurdaydin C, Bozdayi AM. Complete genome sequence and phylogenetic analysis of hepatitis B virus isolated from turkish patients with chronic HBV infection. J Med Virol 2005; 76:476-81.

  7. Pai SB, Bozdayi AM, Pai RB, Beker T, Sarioglu M, Turkyilmaz AR, Grier J, Yurdaydin C, Schinazi RF. Emergence of a novel mutation in the FLLA region of hepatitis B virus during lamivudine therapy. Antimicrob Agents Chemother 2005; 49:2618-24

  8. Toruner M, Erkan O, Soykan I, Bozdayi M, Cetinkaya H, Yurdaydin C, Uzunalimoglu O, Ozden A. Factor V Leiden, prothrombin G20210A and MTHFR gene mutations in inflammatory bowel disease. Turk J Gastroenterol 2004; 15:250-2

  9. Varlı M, Heper AO, Erden E, Uzunalimoglu, Yurdaydın C, Bozkaya. P21 expression and its relation to disease activity and hepatocyte proliferation in chronic hepatitis B virus infection. Turk J Gastroenterol. 2005; 16:12-6.

  10. Kutlu T, Soycan LY, Karatayli E, Turkyilmaz AR, Yurdaydin C, Bozdayi AM. The first identified hepatitis B virus vaccine escape mutation in Turkey. J Clin Virol 2006; 35:201-2

  11. Verdi H, Koytak ES, Onder O, Ergul AA, Cinar K, Idilman R, Erden E, Bozdayi AM, Yurdaydin C, Uzunalimoglu O, Bozkaya H. Peroxisome proliferator-activated receptor alpha L162V polymorphism in nonalcoholic steatohepatitis and genotype 1 hepatitis C virus-related liver steatosis. J Investig Med 2005; 53:353-9

  12. Terzioglu B, Aypak C, Yananli HR, Kucukibrahimoglu E, Yurdaydin C, Goren MZ. 5-hydroxytryptamine release in the anterior hypothalamic and the hippocampal areas of cholestatic rats. Life Sci. 2006; 78:1078-83

  13. Yurdaydın C. Delta hepatitis in Turkey: Decreasing but not vanishing and still of concern. Turk J Gastroenterol 2006; 17:74-5

  14. Craxi A, Yurdaydın C. From viral pathobiology to the treatment of hepatitis B virus infection EASL Monothematic Conference (Istanbul, Turkey, October 6-8, 2005). J Hepatol 2006; 44:1186-95

  15. Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, Boron-Kaczmarska A, Martin P, Goodman Z, Colonno R, Cross A, Denisky G, Kreter B, Hindes R; AI463026 BEHoLD Study Group.Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130:2039-49

  16. Bonino F, Marcellin P, Lau GK, Hadziyannis S, Jin R, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Brunetto M, Farci P, Popescu M, McCloud P. Predicting response to peginterferon alfa-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut. 2007 (in press)

  17. Karataylı E, Karayalçın S, Karraaslan H, Türyılmaz AR, Şahin F, Yurdaydın C, Bozdayı AM. A novel mutation pattern emerging during lamivudine treatment showe cross-resistance to adefovir dipivoxil. Antiviral Ther 2007; 12:761-8

  18. Ferenci P, Czlonkowska A, Merle U, Gromadzka G, Yurdaydın C, et al. Late onset Wison’s disease. Gastroenterology 2007; 132:1294-9

  19. Yurdaydın C, Bozkaya H, Karaaslan H, et al. A pilot study of 2 years of interferon treatment in patients with chronic delta hepatitis. J Viral Hepat 2007; 14:812-6

  20. Koytak ES, Yurdaydin C, Glenn J. Hepatitis D. Curr Treat Options Gastroenterol 2007; 10:456-63

  21. Yurdaydın C, Bozkaya H, Önder FO, et al. Treatment of chronic delta hepatitis with lamivudine vs. lamivudine + interferon vs. interferon. J Viral Hepat 2008; 15:314-21

  22. Değertekin H, Yalçin K, Yakut M, Yurdaydin C. Seropositivity for delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta-analysis. Liver Int 2008; 28:494-8.

  23. Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology; 2008; 48:99-108

  24. Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T,

Luo K, Wang Y, Hadziyannis S, Wolf E, McCloud P, Batrla R, Marcellin P. Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology. 2008;49:1141-1150

  1. Karaaslan H, Yurdaydin C. Viral hepatitis at the Black Sea region: the problem of viral hepatitis in Turkey revisited. Turk J Gastroenterol. 2009; 20:1-2.

  2. Marcellin P, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Jin R, Gurel S, Lu ZM, Wu J, Popescu M, Hadziyannis S; Peginterferon alfa-2a in HBeAg-negative Chronic Hepatitis B Study Group. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alfa-2a. Gastroenterology 2009 136:2169-2179

  3. Idilman R, Kaymakoglu S, Oguz Onder F, Ahishali E, Bektas M, Cinar K, Pinarbasi B, Karayalcin S, Badur S, Cakaloglu Y, Mithat Bozdayi A, Bozkaya H, Okten A, Yurdaydin C. A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients. J Viral Hepat. 2009; 16:279-85

  4. Koytak ES, Mizrak D, Bektaş M, Verdi H, Arslan Ergül A, Idilman R, Cinar K, Yurdaydin C, Ersõz S, Karayalçin K, Uzunalimoğlu O, Bozkaya H. PPAR-alpha L162V polymorphism in human hepatocellular carcinoma. Turk J Gastroenterol. 2008; 19:245-9.

  5. Yurdaydin C. Entecavir: a step forward in combating hepatitis B disease. Expert Opin Pharmacother. 2008; 9:3095-109

  6. Tozun N, Atug O, Imeryuz N, Hamzaoglu HO, Tiftikci A, Parlak E, Dagli U, Ulker A, Hulagu S, Akpinar H, Tuncer C, Suleymanlar I, Ovunc O, Hilmioglu F, Aslan S, Turkdogan K, Bahcecioglu HI, Yurdaydin C; Members of the Turkish IBD Study Group. Clinical Characteristics of Inflammatory Bowel Disease in Turkey: A Multicenter Epidemiologic Survey. J Clin Gastroenterol. 2009; 43:51-7

  7. Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Luo K, Wang Y, Hadziyannis S, Wolf E, McCloud P, Batrla R, Marcellin P. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.. Hepatology 2009; 49:1141-50

  8. Bektaş M, Dökmeci A, Cinar K, Halici I, Oztas E, Karayalcin S, Idilman R, Sarioglu M, Ustun Y, Nazligul Y, Ormeci N, Ozkan H, Bozkaya H, Yurdaydin C. Endoscopic Management of Biliary Parasitic Diseases. Dig Dis Sci 2010; 55:1472-8

  9. Mizrak D, Engin B, Onder FO, Yener B, Bektaş M, Biyikli Z, Idilman R, Cinar K, Karayalçin K, Ersöz S, Karayalçin S, Ozden A, Yurdaydin C, Yazihan N, Ataoğlu H, Bozkaya H, Uzunalimoğlu O. Aflatoxin exposure in viral hepatitis patients in Turkey. Turk J Gastroenterol. 2009 Sep; 20:192-7

  10. Zachou K, Yurdaydin C, Drebber U, et al. Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. Liver Int 2010; 30:430-7

  11. Idilman R, Bektas M, Cinar K, Toruner M, Cerit ET, Doganay B, Erden E, Bozkaya H, Bahar K, Karayalcin S, Soykan I, Palabiyikoglu M, Cetinkaya H, Yurdaydin C, Dokmeci A, Ozden A. The characteristics and clinical outcome of drug-induced liver injury: a single-center experience. J Clin Gastroenterol. 2010 Jul;44(6):e128-32.



  1. Yurdaydın C, Idilman R, Bozkaya H, Bozdayi AM. Natural history and treatment of chronic delta hepatitis.J Viral Hepat 2010; 17:749-56




  1. Wedemeyer H, Yurdaydin C, Dalekos GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011; 364:322-31




  1. Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M, Shiffman ML, Yurdaydin C, Dalgard O. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol. 2011 8(4):212-23

  2. Yurdaydin C, Akarca US. Treatment of chronic hepatitis B with telbivudine: wise hepatologists needed in hepatitis B endemic countries where treatment options are limited. Liver Int. 2011 May;31(5):589-91.

  3. Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C, Dalgard O, Dillion JF, Flisiak R, Forns X, Frankova S, Goldis A, Goulis I, Halota W, Hunyady B, Lagging M, Largen A, Makara M, Manolakopoulos S, Marcellin P, Marinho RT, Pol S, Poynard T, Puoti M, Sagalova O, Sibbel S, Simon K, Wallace C, Young K, Yurdaydin C, Zuckerman E, Negro F, Zeuzem S. A systemic review of hepatitis C virus epidemiology ın Europe, Canada and Israel. Liver Int 2011; 31(Suppl. 2):30-60

  4. Grabowski J, Yurdaydìn C, Zachou K, et al. Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment. Liver Int 2011; 31(9):1395-405

  5. Mederacke I, Filmann N, Yurdaydin C, et al. Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation. J Hepatol 2011; 56(1):115-22

  6. Seven G, Karatayli SC, Köse SK, Yakut M, Kabaçam G, Törüner M, Heper AO, Voelker M, Erden E, Bozdayi AM, Uzunalımoğlu O, Bozkaya H, Yurdaydin C, Schuppan D. Serum connective tissue markers as predictors of advanced fibrosis in patients with chronic hepatitis B and D. Turk J Gastroenterol 2011; 22(3):305-14

  7. Celik I, Karatayli E, Cevik E, Kabakçi SG, Karatayli SC, Dinç B, Cinar K, Yalçin K, Idilman R, Yurdaydin C, Bozdayi AM. Complete genome sequences and phylogenetic analysis of hepatitis delta viruses isolated from nine Turkish patients. Arch Virol 2011; 156(12):2215-20

  8. Karatayli E, Karatayli SC, Cinar K, Gokahmetoglu S, Güven K, Idilman R, Yurdaydin C, Bozdayi AM. Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection. J Clin Virol 2011; 53(2):130-4

  9. Toy M, Onder FO, Wörmann T, Bozdayi AM, Schalm SW, Borsboom GJ, van Rosmalen J, Richardus JH, Yurdaydin C. Age- and region-specific hepatitis B prevalence in Turkey estimated using generalized linear mixed models: a systematic review. BMC Infect Dis 2011; 11(1):337

  10. Mederacke I, Yurdaydin C, Dalekos GN, et al. Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-α2a treatment. Antivir Ther. 2012;17(2):305-12

  11. Idilman R, Cinar K, Seven G, Bozkus Y, Elhan A, Bozdayi M, Yurdaydin C, Bahar K. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients. J Viral Hepat. 2012; 19(3):220-6

  12. Quigley EM, Yurdaydin C. First WGO regional meeting with the TSG: a template for future regional gastroenterology collaborations. Expert Rev Gastroenterol Hepatol. 2012 Apr;6(2):141-3.

  13. Yurdaydin C, Quigley EM. Gastro-Antalya 2011: A Successful Regional Meeting Between the WGO and the TSG. J Clin Gastroenterol. 2012 Apr;46(4):i-ii

  14. Bozdayi AM, Karatayli SC, Alagöz SG, Mizrak D, Sayki M, Ozkan M, Savaş B, Erden E, Cinar K, Idılman R, Yurdaydin C. Potential proteomic biomarkers in assessing liver fibrosis using SELDI-TOF MS. Turk J Gastroeneterol 2012; 23:46-53

  15. Yurdaydin C, Mullen KD, Bergasa NV. Obituary: E. Anthony Jones, M.D. Liver Int 2012; 32:871-2

  16. Kabaçam G, Önder FO,Yakut M, Seven G, Karataylı SC. Karataylı E, Savaş B, Idilman R, Bozdayı AM, Yurdaydın C. Entecavir treatment of chronic delta hepatitis. Clin Inf Dis 2012; 55(5):645-50

  17. Yurdaydın C. Treatment of chronic delta hepatitis. Sem Liver Dis 2012; 32(3):237-44

  18. Mederacke I, Yurdaydin C, Großhennig A, Erhardt A, Cakaloglu Y, Yalcin K, Gurel S, Zeuzem S, Zachou K, Chatzikyrkou C, Bozkaya H, Dalekos GN, Manns MP, Wedemeyer H; Hep-Net/International Delta Hepatitis Study Group. Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection. J Viral Hepat. 2012 Jun;19(6):387-95

  19. Heidrich B, Serrano BC, Idilman R, Kabaçam G, Bremer B, Raupach R, Önder FO, Deterding K, Zacher BJ, Taranta A, Bozkaya H, Zachou K, Tillmann HL, Bozdayi AM, Manns MP, Yurdaydın C, Wedemeyer H. HBeAg-positive hepatitis delta: virological patterns and clinical long-term outcome. Liver Int. 2012 Oct;32(9):1415-25

  20. Toy M, Onder FO, Idilman R, Kabacam G, Richardus JH, Bozdayi M, Akdogan M, Kuloglu Z, Kansu A, Schalm S, Yurdaydin C. The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country. Eur J Health Econ. 2012 Oct;13(5):663-76

  21. Karatayli E, Idilman R, Karatayli SC, Cevik E, Yakut M, Seven G, Kabaçam G, Bozdayi AM, Yurdaydin C. Clonal analysis of the quasispecies of antiviral resistant HBV genomes in patients with entecavir resistance during rescue treatment and successful treatment of entecavir resistance with tenofovir. Antivir Ther. 2013; 18:77-85

  22. Chan HL, Chen YC, Gane EJ, Sarin SK, Suh DJ, Piratvisuth T, Prabhakar B, Hwang SG, Choudhuri G, Safadi R, Tanwandee T, Chutaputti A, Yurdaydin C, Bao W, Avila C, Trylesinski A. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis. J Viral Hepat. 2012 Oct;19(10):732-43

  23. Nishimura T, Hu Y, Wu M, Pham E, Suemizu H, Elazar M, Liu M, Idilman R, Yurdaydin C, Angus P, Stedman C, Murphy B, Glenn J, Nakamura M, Nomura T, Chen Y, Zheng M, Fitch WL, Peltz G. Using Chimeric Mice with Humanized Livers to Predict Human Drug Metabolism and a Drug-Drug Interaction. J Pharmacol Exp Ther. 2013; 34:388-96

  24. Kabaçam G, Dalekos GN, Cakaloğlu Y, Zachou K, Bock T, Erhardt A, Zeuzem S, Tabak F, Yalçin K, Bozdayi AM, Dienes HP, Bozkaya H, Manns M, Wedemeyer H, Yurdaydin C. Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis. Turk J Gastroenterol. 2012 Oct;23(5):560-8.

  25. Marcellin P, Bonino F, Yurdaydin C, Hadziyannis S, Moucari R, Kapprell HP, Rothe V, Popescu M, Brunetto MR. Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. Hepatol Int. 2013;7(1):88-97

  26. Brunetto MR, Marcellin P, Cherubini B, Yurdaydin C, Farci P, Hadziyannis SJ, Rothe V, Regep L, Bonino F. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: On-treatment kinetics of HBsAg serum levels vary by HBV genotype. J Hepatol. 2013 59(6):1153-9

  27. Kabaçam G, Wedemeyer H, Savaş B, Keskin O, Dalekos G, Tabak F, Idilman R, Erhardt A, Yalçın K, Bozdayi MA, Bozkaya H, Manns M, Dienes H, Yurdaydın C. Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta. Liver Int. 2014 Sep;34(8):1207-15

  28. Keskin O, Ormeci AC, Baran B, Kabaçam G, Tüzün A, Karatayli E, Akyüz F, Karatayli S, Bozdayi AM, Onel D, Badur S, Idilman R, Kaymakoglu S, Yurdaydin C. Efficacy of tenofovir in adefovir-experienced patients compared with treatment-naive patients with chronic hepatitis B. Antiviral Ther 2014; 19(6):543-50

  29. Bektas M, Seven G, Idilman R, Yakut M, Doğanay B, Kabacam G, Ustun Y, Korkut E, Kalkan Ç, Sahin G, Cetinkaya H, Bozkaya H, Yurdaydin C, Bahar K, Cinar K, Soykan I. Manometric assessment of esophageal motor function in patients with primary biliary cirrhosis.Eur J Intern Med 2014; 25(3):230-4

  30. Heidrich B, Yurdaydın C, Kabaçam G, Ratsch BA, Zachou K, Bremer B, Dalekos GN, Erhardt A, Tabak F, Yalcin K, Gürel S, Zeuzem S, Cornberg M, Bock CT, Manns MP, Wedemeyer H; HIDIT-1 Study Group. Hepatology 2014; 60(1):87-97

  31. Karataylı E, Altunoğlu YÇ, Karataylı SC, Alagöz SG, Cınar K, Yalçın K, Idilman R, Yurdaydın C, Bozdayı AM. A one step real time PCR method for the quantification of hepatitis delta virus RNA using an external armored RNA standard and intrinsic internal control. J Clin Virol 2014; 60(1):11-5

  32. Karatayli SC, Ulger ZE, Ergul AA, Keskin O, Karatayli E, Albayrak R, Ozkan M, Idilman R, Yalcin K, Bozkaya H, Uzunalimoğlu O, Yurdaydin C, Bozdayi AM. Tumour necrosis factor-alpha, interleukin-10, interferon-gamma and vitamin D receptor gene polymorphisms in patients with chronic hepatitis delta. J Viral Hepat 2014; ;21(4):297-304

  33. Karataylı SC, Bozdayı M, Karataylı E, Öztürk T, Husseini AA, Albayrak R, Özkan M, Kalaylıoğlu Z, Yalçın K, Çınar K, İdilman R, Yurdaydın C. Interleukin-28 gene polymorphisms may contribute to HBsAg persistence and the development of HBeAg-negative chronic hepatitis B. Liver Int 2015; 35(3):846-53

  34. Jalan R, Yurdaydin C, Bajaj JS, Acharya SK, Arroyo V, Lin HC, Gines P, Kim WR, Kamath PS; World Gastroenterology Organization Working Party. Toward an improved definition of acute-on-chronic liver failure. Gastroenterology 2014; 147(1):4-10

  35. Karataylı E, Altunoğlu YÇ, Karataylı SC, Yurdaydın C, Bozdayı AM. Free circulating nucleic acids in plasma and serum as a novel approach to the use of internal controls in real time PCR based detection.J Virol Methods 2014; 207:133-7

  36. Wranke A, Heidrich B, Ernst S, Calle Serrano B, Caruntu FA, Curescu MG, Yalcin K, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Bremer B, Stift J, Grabowski J, Kirschner J, Port K, Cornberg M, Falk CS, Dienes HP, Hardtke S, Manns MP, Yurdaydin C, Wedemeyer H. Anti-HDV IgM as a marker of disease activity in hepatitis delta. PLoS One. 2014 Jul 29;9(7):e101002

  37. Papatheodoridis GV, Dalekos GN, Yurdaydin C, Buti M, Goulis J, Arends P, Sypsa V, Manolakopoulos S, Mangia G, Gatselis N, Keskın O, Savvidou S, Hansen BE, Papaioannou C, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL, Lampertico P. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir.J Hepatol 2015; ;62(2):363-70.

  38. Kabakçı Alagöz G, Karataylı SC, Karataylı E, Celik E, Keskin O, Dinç B, Cınar K, Idilman R, Yurdaydın C, Bozdayı AM. Hepatitis C virus genotype distribution in Turkey remains unchanged after a decade: performance of phylogenetic analysis of the NS5B, E1, and 5'UTR regions in genotyping efficiency.Turk J Gastroenterol 2014; 25(4):405-10

  39. Idilman R, Gunsar F, Koruk M, Keskin O, Meral CE, Gulsen M, Elhan AH, Akarca US, Yurdaydin C. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting.J Viral Hepat 2015; 22(5):504-10

  40. Keskin O, Wedemeyer H, Tüzün A, Zachou K, Deda X, Dalekos GN, Heidrich B, Pehlivan S, Zeuzem S, Yalçın K, Gürel S, Tabak F, Idilman R, Bozkaya H, Manns M, Yurdaydin C. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome.Clin Gastroenterol Hepatol 2015; 13(13):2342-49

  41. Koh C, Canini L, Dahari H, Zhao X, Uprichard SL, Haynes-Williams V, Winters MA, Subramanya G, Cooper SL, Pinto P, Wolff EF, Bishop R, Ai Thanda Han M, Cotler SJ, Kleiner DE, Keskin O, Idilman R, Yurdaydin C, Glenn JS, Heller T. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.Lancet Infect Dis 2015; 15(10):1167-74

  42. Yurdaydin C, Idilman R. Therapy of Delta Hepatitis. Cold Spring Harb Perspect Med. 2015 Aug 7;5(10). pii: a021543. doi: 10.1101/cshperspect.a021543.

  43. Papatheodoridis G, Dalekos G, Sypsa V, Yurdaydin C, Buti M, Goulis J, Calleja JL, Chi H, Manolakopoulos S, Mangia G, Gatselis N, Keskin O, Savvidou S, de la Revilla J, Hansen BE, Vlachogiannakos I, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL, Lampertico P. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.J Hepatol 2016; 64(4):800-6

  44. Lutterkort GL, Wranke A, Yurdaydin C, Budde E, Westphal M, Lichtinghagen R, Stift J, Bremer B, Hardtke S, Keskin O, Idilman R, Koch A, Manns MP, Dienes HP, Wedemeyer H, Heidrich B. Non-Invasive Fibrosis Score for Hepatitis Delta. Liver Int. Liver Int. 2017 Feb;37(2):196-204

  45. Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, Gurel S, Caruntu FA, Flaherty JF, Massetto B, Kim K, Kitrinos KM, Subramanian GM, McHutchison JG, Yee LJ, Elkhashab M, Berg T, Sporea I, Yurdaydin C, Husa P, Jablkowski MS, Gane E. Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study. J Hepatol 2017; 66:1-8

  46. Lim SG, Aghemo A, Chen PJ, Dan YY, Gane E, Gani R, Gish RG, Guan R, Jia JD, Lim K, Piratvisuth T, Shah S, Shiffman ML, Tacke F, Tan SS, Tanwandee T, Win KM, Yurdaydin C. Management of hepatitis C virus infection in the Asia-Pacific region: an update. Lancet Gastroenterol Hepatol. 2017 Jan;2(1):52-62. 

  47. Karakaya F, Özer S, Kalkan Ç, Tüzün EA, Çalışkan A, Keskin O, Kabaçam G, Karatayli S, Karatayli E, Bozdayi AM, Idilman R, Yurdaydin C. Discontinuation of lamivudine treatment in HBeAg-negative chronic hepatitis B: a pilot study with long-term follow-up. Antivir Ther. 2017 Feb 27. doi: 10.3851/IMP3144. [Epub ahead of print]


Book Chapters (international)



  1. Yurdaydın C, Jones EA: Hepatic encephalopathy (Book Chapter). In: Principle and Practice of Gastroenterology and Hepatology, 2nd edition, G. Gitnict, eds., Elsevier Science Publishing Co., Inc. 1994; pp. 985-995

  2. Wedemeyer H, Yurdaydin C. Delta hepatitis. In: Handbuch hepatitis B- Diagnostik, Verlauf, Therapie.Uni-Med Verlag AG, HL Tillmann, ed., 2. Auflage, 2010, pp. 96-102

  3. Yurdaydin C, Bozdayi AM, Idilman R, Bozkaya H. New drugs for hepatitis B: what is in the pipeline? In: Clinical Dilemnas in Viral Liver Disease. Wiley-Blackwell Publ., GR Foster & KR Reddy eds., 2010, pp. 226-9

  4. Yurdaydin C, Idilman R. Hepatic encephalopathy. Textbook of Hepato-Gastroenterology (in press)


Contributions to International Meeting Books:


  1. Yurdaydın C, Walsh TJ, Engler HD, Basile AS, Jones EA.The role of gut bacteria in the accumulation of benzodiazepine receptor ligands in hepatic encephalopathy.In: Advances in Hepatic Encephalopathy and Metabolic Nitrogen Exchange, Capocaccia L, Merli M, Riggio O (Eds). CRC Press, Boca Raton, FL, 1995 pp. 193-7.

  2. Jones EA, Yurdaydın C, Basile AS. Benzodiazepine antagonists and the management of hepatic encephalopathy. In: Advances in Hepatic Encephalopathy and Metabolic Nitrogen Exchange, Capocaccia L, Merli M, Riggio O (Eds). CRC Press, Boca Raton, FL, 1995; pp. 549-63.

  3. Basile AS, Gu Z-Q, Yurdaydın C, Harrison PM, Hughes RD, Pannell L, McKinney A, Jones EA, Williams R. The relationship between benzodiazepine receptor ligand concentrations and the severity of hepatic encephalopathy in humans and animal models of acute liver failure. In:Advances in hepatic encephalopathy and metabolic nitrogen exchange, Capocaccia L, Merli M, Riggio O(Eds).CRC Press, Boca Raton, FL,1995; pp. 198-202.

  4. Püspök A, Hörtnagl H, Herneth A, Steindl P, Yurdaydın C, Roth E, Ferenci P. Influence of branched chain amino acids on glutamine levels in rats with Hyperammonemia due to urease treatment or acute liver failure. In:Advances in Hepatic encephalopathy and metabolic nitrogen exchange, Capocaccia L, Merli M, Riggio O (Eds).CRC Press, Boca Raton, FL, 1995; pp. 198-204.

  5. Herneth AM, Püspök A, Steindl P, Yurdaydın C, Ferenci P. The influence of serotonin antagonists on hepatic encephalopathy in rast with thioacetamide-İnduced liver failure. In: Advances in hepatic encephalopatyh and metabolic nitrogen exchange, Capocaccia L, Merli M, Riggio O (Eds).CRC Press, Boca Raton, FL, 1995; pp. 254-58.

  6. Yurdaydın C, Swain MG, Vergalla J, Paul SM, Jones EA. Effect of inhibition of ornithine decarboxylase activity in two animal models of fulminant hepatic failureinduced by hepatotoxins. In: Advances in Hepatic Encephalopathy and Metobolism in Liver Disease, Ipswich Book Co.Ltd., Record CE, AL Mardini H, Eds., 1997; pp. 45-54

  7. Yurdaydın C, Li Y, Ha J-H, Jones EA, Basile AS. Changes in brain and plasma opioid peptide levels in fulminant hepatic failure: implications for antagonist therapy. In: Advances in Hepatic Encephalopathy and Metabolism in Liver Disease, Ipswich Book Co. Ltd., Record CE, AL Mardini H, eds., 1997; pp.215-22.

  8. Çınar K, Bozdayı M, Bozkaya H, Uzunalimoğlu Ö, Erekul S and Yurdaydın C. Hepatic encephalopathy (Book Chapter). Possible mechanisms of the hepatoprotective effect of difluoromethylornithine on Thioacetamide-induced fulminant hepatic failure in the rat.. Inc. 1999; pp. 59-66.

  9. Hanus L, Yurdaydin C, Bektaş A, Basile AS. Hepatic encephalopathy (Book Chapter). Does oleamide contribute to hepatic encephalopathy (HE)? Inc. 1999; pp. 179-186.

  10. Cınar K, Uzunalimoğlu O, Erekul S, Bozkaya H, Bozdayı M, Yurdaydin C. N-Acetylcysteine in thiocetamide induced toxic hepatitis in rats. 1999;pp. 453-459.

  11. Çelik T, Gören MZ, Gürdal H, Çinar K, Törüner M, Değim T, Uzbay IT, Bozkaya H and Yurdaydin C. Hepatic encephalopathy. (Book Chapter). Is fatigue of cholestasis mediated by altered central serotoninergic neurotransmission? Inc. 2003; pp. 165-171.

  12. Göktürk S, Deda G, Bozkaya H and Yurdaydin C. Hepatic encephalopathy. (Book Chapter). Naloxone treatment of human hepatic encephalopathy. Inc. 2003; pp. 369-374.






Directory: wp-content -> uploads -> 2017
2017 -> Leadership ohio
2017 -> Ascension Lutheran Church Counter’s Schedule January to December 2017
2017 -> Board of directors juanita Gibbons-Delaney, mha, rn president 390 Stone Castle Pass Atlanta, ga 30331
2017 -> Military History Anniversaries 16 thru 31 January Events in History over the next 15 day period that had U. S. military involvement or impacted in some way on U. S military operations or American interests
2017 -> The Or Shalom Cemetery Community Teaching on related issues of Integral
2017 -> Ford onthult samenwerking met Amazon Alexa en introduceert nieuwe navigatiemogelijkheden van Ford sync® 3 met Applink
2017 -> Start Learn and Increase gk. Question (1) Name the term used for talking on internet with the help of text messege?
2017 -> Press release from 24. 03. 2017 From a Charleston Car to a Mafia Sedan
2017 -> Tage Participants
2017 -> Citi Chicago Debate Championship Varsity and jv previews

Download 101.12 Kb.

Share with your friends:



The database is protected by copyright ©ininet.org 2024
send message
    Main page
national institutes
editorial board
scientific committee
cost-effectiveness